US 12,357,586

Application 17/585,415 · Granted Jul 15, 2025

Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy

Estimated expiration

January 3, 2032

5y 44d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTGB2012050002: Resource not found (404)
Earliest effective filing
Jan 3, 2012
+ 20 years
Jan 3, 2032
PTA +0d
Jan 3, 2032
No TD
—
Final
Jan 3, 2032

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
January 26, 2022
Earliest effective filing
January 3, 2012
Issue date
July 15, 2025
PTA
0 days
Base expiry (before PTA)
January 3, 2032

January 3, 2012 + 20 years = January 3, 2032

  • Continuation of application 13/977,766, filed Jul 1, 2013
  • National stage entry of application PCTGB2012050002, filed Jan 3, 2012
  • National stage entry of application PCTGB2012050002, filed Jan 3, 2012

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/585,415 · US 12,357,586

PatentReply compiles the prosecution history behind US 12,357,586: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12357586

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.